Faculty Information - Ryoko Sakai

（Last updated : 2024-03-25 23:39:37）

Ryoko Sakai
Department School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine Department of Internal Medicine, Division of Rheumatology

Position

■ Published papers

1.	Original article	Nationwide clinical and epidemiological study of large-vessel vasculitis in Japan in 2017. 2023/02
2.	Original article	Association between patient-reported outcomes and impairments in work and activity in patients with rheumatoid arthritis in clinical remission: a retrospective analysis using the IORRA database. 2022/09
3.	Original article	Differences in patients' population and efficacy/effectiveness of biologic disease-modifying antirheumatic drugs between randomized controlled trials and real-world settings in patients with rheumatoid arthritis - using the IORRA cohort. 2022/07/01
4.	Original article	Unincreased risk of hospitalized infection under targeted therapies versus methotrexate in elderly patients with rheumatoid arthritis: a retrospective cohort study. 2022/06
5.	Original article	Geographic variations in rheumatoid arthritis treatment in Japan: A nationwide retrospective study using the national database of health insurance claims and specific health checkups of Japan. 2022/01
6.	Original article	Subjective symptoms contributing to the quality of life of rheumatoid arthritis patients with clinical remission from the IORRA database. 2022
7.	Original article	The risk of hospitalized infection in patients with systemic lupus erythematosus treated with hydroxychloroquine. 2020/11
8.	Original article	Risk of opportunistic infections in patients with antineutrophil cytoplasmic antibody-associated vasculitis, using a Japanese health insurance database. 2019/07
9.	Original article	No increased risk of herpes zoster in TNF inhibitor and non-TNF inhibitor users with rheumatoid arthritis: epidemiological study using the Japanese health insurance database. 2018/09
10.	Original article	Association Between Medications and Herpes Zoster in Japanese Patients with Rheumatoid Arthritis: A 5-year Prospective Cohort Study. 2017/07
11.	Original article	High prevalence of cardiovascular comorbidities in patients with rheumatoid arthritis from a population-based cross-sectional study of a Japanese health insurance database. 2016/07
12.	Original article	Pulmonary infections following immunosuppressive treatments during hospitalization worsen the short-term vital prognosis for patients with connective tissue disease-associated interstitial pneumonia. 2015/07
13.	Original article	Assessment of risks of pulmonary infection during 12 months following immunosuppressive treatment for active connective tissue diseases: a large-scale prospective cohort study. 2015/04
14.	Original article	The risk of serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors decreased over time: a report from the registry of Japanese rheumatoid arthritis patients on biologics for long-term safety (REAL) database. 2014/12
15.	Original article	A comparison of incidence and risk factors for serious adverse events in rheumatoid arthritis patients with etanercept or adalimumab in Korea and Japan. 2014/07
16.	Original article	Clinical characteristics and risk factors for Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis receiving adalimumab: a retrospective review and case-control study of 17 patients. 2013/11
17.	Original article	Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules. 2012/11
18.	Original article	Pneumocystis jirovecii pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors. 2012/11
19.	Original article	Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis. 2012/08
20.	Original article	The REAL database reveals no significant risk of serious infection during treatment with a methotrexate dose of more than 8 mg/week in patients with rheumatoid arthritis. 2011/08
Display 5 items
Display all(20)

■ Awards & honors

1.	2019/09	East Asian Group of Rheumatology Travel Award
2.	2017/07	East Asian Group of Rheumatology Young Investigator Award
3.	2012/04	日本リウマチ学会日本リウマチ学会国際ワークショップ賞

■ Academic society memberships

1.	2010/04～	Japanese Society for Pharmacoepidemiology
2.	2008/10～	Japan College of Rheumatology

■ Education

1.	2016/04～2018/03	〔Master degree program〕, Faculty of Medicine, The University of Tokyo, Completed,
2.	2008/04～2012/03	〔Doctoral course〕, Tokyo Medical and Dental University, Completed,

■ Academic & professional experience

2012/04～2015/07

Tokyo Medical and Dental University Department of Pharmacovigilance Assistant Professor